Bnp Paribas Asset Management Holding S.A. Vaxcyte, Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $41 Billion
- Q2 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 1,218 shares of PCVX stock, worth $36,418. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,218Holding current value
$36,418% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
332Shares Held
136MCall Options Held
348KPut Options Held
250K-
Ra Capital Management, L.P. Boston, MA12.2MShares$364 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$360 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$352 Million0.25% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$297 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$192 Million0.05% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $1.77B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...